OncoMatch/Clinical Trials/NCT06855069
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Is NCT06855069 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including HS-20089 and Paclitaxel for ovarian cancer.
Treatment: HS-20089 · Paclitaxel · Doxorubicin · Topotecan — This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Patients must have platinum-resistant disease
Cannot have received: TOP1 inhibitor
Prior treated with TOP1 inhibitors
Cannot have received: antibody-drug conjugate
Exception: if payload is TOP1 inhibitor
ADCs with TOP1 inhibitors as payload
Lab requirements
Blood counts
adequate bone marrow reserve
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate bone marrow reserve and organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06855069 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TOP1 inhibitor, antibody-drug conjugate disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages